At our Phacilitate Special Interest Group: Automation held in 2017, the focus was firmly on creating a roadmap towards 'Automation in Cell-based Therapy Manufacturing and Supply Chain'.
Each of the working groups covered a specific theme or question and was tasked with arriving at a specific ‘output’, conclusions, or better yet, action points for the sector as a whole to take forward and utilize in helping drive progress, whether that be in the realm of regulatory guideline development, standardisation, technology development, or defining strategic models for engagement for all stakeholders. Cell-based therapies leverage a diverse range of cell types to treat a range of diseases including, but not limited to cancer, neurodegenerative disease, and heart disease. There are however a number of differing translational challenges to overcome, and given the broad range of technologies in development, this creates a complex commercial landscape.
Manufacturing presents a core issue in CBT commercialisation, and in this exclusive report produced in partnership with BioLacuna, we explore the role of automation in manufacturing risk management.